Neximmune Performance
| NEXIDelisted Stock | USD 2.43 0.22 9.95% |
The company secures a Beta (Market Risk) of -1.83, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Neximmune are expected to decrease by larger amounts. On the other hand, during market turmoil, Neximmune is expected to outperform it. Neximmune right now secures a risk of 0.0%. Please verify Neximmune potential upside, rate of daily change, as well as the relationship between the Rate Of Daily Change and period momentum indicator , to decide if Neximmune will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neximmune has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Neximmune is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 34.7 M |
Neximmune |
Neximmune Relative Risk vs. Return Landscape
If you would invest 243.00 in Neximmune on August 27, 2024 and sell it today you would earn a total of 0.00 from holding Neximmune or generate 0.0% return on investment over 90 days. Neximmune is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Neximmune, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neximmune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neximmune's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Neximmune, and traders can use it to determine the average amount a Neximmune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NEXI |
Based on monthly moving average Neximmune is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neximmune by adding Neximmune to a well-diversified portfolio.
Neximmune Fundamentals Growth
Neximmune Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Neximmune, and Neximmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neximmune Pink Sheet performance.
| Return On Equity | -1.96 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | (491.95 K) | ||||
| Shares Outstanding | 1.37 M | ||||
| Price To Book | 1.38 X | ||||
| EBITDA | (28.17 M) | ||||
| Cash And Equivalents | 53.13 M | ||||
| Cash Per Share | 2.20 X | ||||
| Total Debt | 68.81 K | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (31.43 M) | ||||
| Earnings Per Share | (24.11) X | ||||
| Total Asset | 8.59 M | ||||
| Retained Earnings | (222.59 M) | ||||
About Neximmune Performance
By evaluating Neximmune's fundamental ratios, stakeholders can gain valuable insights into Neximmune's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neximmune has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neximmune has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.Things to note about Neximmune performance evaluation
Checking the ongoing alerts about Neximmune for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Neximmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neximmune is not yet fully synchronised with the market data | |
| Neximmune has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (32.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neximmune currently holds about 53.13 M in cash with (31.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.2. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Neximmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neximmune's stock is overvalued or undervalued compared to its peers.
- Examining Neximmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neximmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neximmune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neximmune's pink sheet. These opinions can provide insight into Neximmune's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |